Hello, Welcome to Shine Consultant !
Summit & Event Advisor & Insight Research & Analysis
Guest Information
发布时间: 2020 - 11 - 26
点击次数: 0
Positions: Founder,Chairman and CEO
Company: Elixiron Immunotherapeutics, Inc.
个人简介:
Kevin is the founder, Chief Executive Officer and Chairman of the board of Elixiron Immunotherapeutics.  Over the course of his career, Kevin has been committed to advancing the development of breakthrough treatments with specific emphasis on translational medicine.  Most recently, he served as Senior Vice President and Chief Medical Officer of Eusol Biotech Co., Ltd., a clinical stage company focused on developing therapeutic biologics for neurological diseases.  Prior to Eusol, Kevin served as Director of Translational Medicine at Development Center for Biotechnology (DCB), Taiwan, where he led an initiative to implement translational medicine strategy across drug development stages. Kevin played a key role in strategic planning and building DCB’s immune-oncology portfolio, and led the development of preclinical candidates of anti-TIM3 and CSF1R inhibitor for cancer immunotherapy. Prior to DCB, Kevin was Principal Scientist at GlaxoSmithKline’s Neuroimmunology Discovery Performance Unit in Shanghai.  There, he led an integrated project team and successfully moved a novel drug discovery project from target identification/validation, high throughput screen, to lead optimization.  Kevin also served on global development teams, leading the biomarker and translational studies for a Ph2 clinical trial.  Prior to joining GSK, Kevin served as Assistant Investigator at Translational Research Center of Gladstone Institutes, San Francisco.  He actively participated in a multi-million dollar academia-industry collaborative project with Merck & Co., Inc. for the development of small molecule drugs for treating Alzheimer’s disease.  Kevin earned his M.D. and Ph.D. from National Yang-Ming University and completed postdoctoral training at Baylor College of Medicine and Howard Hughes Medical Institute at Houston, Texas.  Kevin has authored or co-authored several peer-reviewed manuscripts in the leading’s journals including Cell, Nature Medicine and Nature Communications.
发布时间: 2020 - 11 - 26
点击次数: 0
Positions: President, Asia Pacific, IQVIA
Company: IQVIA
个人简介:
waiting
发布时间: 2020 - 11 - 26
点击次数: 0
Positions: CEO and Co-Founder
Company: AnHeart Therapeutics (Hangzhou) Co., Ltd.
个人简介:
Dr. Wang co-founded AnHeart Therapeutics with other two co-founders in 2018. Before AnHeart, he severed as Head of Global Biostatistics, Epi and Medical Writing at Merck Serono, China.  Before Merck Serono, he served various leadership role in global clinical development and medical research at BMS, Wyeth/Pfizer, The Medicines Company, and Merck & Co. His drug development experience includes therapeutic areas such as oncology, cardiovascular, neuroscience, immunology, and hematology. He has played a critical role in two successful NDAs for the US market and other worldwide markets. Besides his many interactions with FDA and EMA, he has also played a critical role in communications with PMDA and NMPA for label extension submissions.  Dr. Wang serves as a global expert for two NMPA/CDE ICH working groups.  Dr. Wang earned BS from the University of Science and Technology of China and PhD from Iowa State of University.
发布时间: 2020 - 11 - 26
点击次数: 0
Positions: Director, BD & Licensing, BioInnovation Asia
Company: Servier
个人简介:
Cynthia Wang Joined Servier China as Business Development Director since July 2015.  Cynthia brings with her over 19 years of Healthcare/pharmaceutical industrial experience in China.  Prior to Servier China, Cynthia worked as Senior BD manager for Pfizer in Vaccine BD global M&A projects and managing full TAs of out-licensing BD activities. Before joining Pfizer, Cynthia held a series of positions in Business Development, New Product Introduction, Product launch, Strategic Alliance Management, Business planning and Operational Management at Janssen/Johnson & Johnson, Agilent Technologies and Schneider Electric. Cynthia has broad BD network in China serving as Vice Chairman of CHBD(China Healthcare BD) organization, Cynthia has proven BD track records of closing multiple BD deals. Cynthia holds a Master of Business Administration from Peking University, a Master of Global Finance from Fordham University in NYC, a Pharmacy degree from Peking University Health Science Centre.